Provided by Dow Jones By Erik Holm and Francesca Fontana Moderna Inc. U.S. health regulators late Friday permitted use of Moderna's Covid-19 vaccine, the second shot to get the green light to help end the pandemic. The Food and Drug Administration's authorization comes a week after the agency authorized the first shot in the U.S., from Pfizer Inc. and its partner BioNTech SE. Moderna, a ten-year-old biotech that has never had a product cleared by the FDA, expects to deliver a total of 20 million doses by the end of December. Moderna shares rose 5.1% Thursday when an advisory panel cleared the way for Friday night's authorization.